#4-61E. Precision Prevention: Rethinking Aspirin in Giant Cell Arteritis (JAMA Netw Open, 2026)

Is low-dose aspirin universally necessary for primary cardiovascular prevention in patients with giant cell arteritis (GCA)? This episode delves into a study investigating the real-world impact of initiating low-dose aspirin at GCA diagnosis. Using a target trial emulation approach on a nationwide French cohort, researchers evaluated the association between low-dose aspirin and the risk of major adverse cardiovascular events (MACE). The findings revealed that aspirin initiation was associated with a reduced risk of MACE at one and three years, but it concurrently increased the risk of major hemorrhage at one year. The most critical and novel discovery of this study is that the cardiovascular benefits of aspirin were notably more pronounced in women and in patients with concurrent diabetes. However, when critically appraising this paper, clinicians must consider that its retrospective observational design means unmeasured confounding factors cannot be entirely ruled out. For our listeners, this study is highly relevant as it challenges routine prescribing practices in GCA. It underscores the need for personalized medicine, guiding physicians to carefully balance ischemic protection against bleeding risks based on individual patient characteristics like sex and diabetic status.

Citation: Beydon M, Tubach F. Low-Dose Aspirin for Cardiovascular Disease Primary Prevention in Patients With Giant Cell Arteritis. JAMA Network Open. 2026. DOI: 10.1001/jamanetworkopen.2026.6579

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.